Characteristics and evidence-based management of stable coronary artery disease patients in Canada compared with the rest of the world: insights from the CLARIFY registry

Gandhi, S., Dorian, P., Greenlaw, N., Tardif, J.-C., Steg, P.G., Huynh, T., Wong, G.C., Love, M.P., Poirier, P. and Goodman, S.G. (2014) Characteristics and evidence-based management of stable coronary artery disease patients in Canada compared with the rest of the world: insights from the CLARIFY registry. Canadian Journal of Cardiology, 30(1), pp. 132-137. (doi:10.1016/j.cjca.2013.07.680) (PMID:24238756)

Full text not currently available from Enlighten.

Abstract

Background: Previous Canadian high vascular risk registries have demonstrated suboptimal goal-directed reductions in cardiovascular risk factors and underutilization of guideline-recommended therapies in part because of physician underestimation of cardiovascular risk.

Methods: The Prospective Observational Longitudinal Registry of Patients With Stable Coronary Artery Disease (CLARIFY) registry enrolled 33,438 stable coronary artery disease patients in 45 countries. In Canada, supplemental information was obtained specifying reasons that patients were not taking guideline-recommended medications.

Results: In Canada, 1232 patients (9 provinces, 110 physicians) were enrolled and in comparison with the rest of the world, there were several differences in cardiovascular risk factors and medical history; in addition, the Canadian cohort had undergone less percutaneous coronary intervention, but more coronary artery bypass grafting. Among the Canadian cohort, many still continue to smoke (13%) and many do not meet secondary prevention targets for waist circumference (54%), body mass index (81%), physical activity (71%), cholesterol (43%), and systolic blood pressure (20%). Nevertheless, the use of guideline-recommended cardiovascular therapy was high and >90% reported partial/full financial coverage for medications. The number of patients not receiving guideline-recommended therapies because of apparent underestimation of risk was particularly low for antiplatelet agents (2%), β-blockers (11%), and lipid-lowering therapies (1%).

Conclusions: Canadian patients with stable coronary artery disease did not meet several guideline-recommended secondary prevention targets, despite high use of evidence-based therapy, extensive financial coverage for these medications, and low physician underestimation of risk. Additional work is needed to identify and address the remaining barriers to effective risk factor control.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Greenlaw, Miss Nicola
Authors: Gandhi, S., Dorian, P., Greenlaw, N., Tardif, J.-C., Steg, P.G., Huynh, T., Wong, G.C., Love, M.P., Poirier, P., and Goodman, S.G.
College/School:College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Robertson Centre
Journal Name:Canadian Journal of Cardiology
Publisher:Pulsus Group Inc
ISSN:0828-282X
ISSN (Online):1557-3117

University Staff: Request a correction | Enlighten Editors: Update this record